Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. ilca

iLCA SIGNED

Intelligent Live Cell Analysis [iLCA] to transform disease management through faster, and more regulatory robust, discovery, manufacture and monitoring of biologic drugs & cell therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 iLCA project word cloud

Explore the words cloud of the iLCA project. It provides you a very rough idea of what is the project "iLCA" about.

disease    transformative    marketed    entry    behalf    cells    time    continued    patients    of    medicines    master    suited    cheaper    quality    potentially    innovation    faster    complete    critical    companies    vivo    commercial    single    imaging    competition    entire    cld    crude    image    editing    shed    attracting    therapy    ing    consuming    markets    forefront    recording    speed    diagnostic    automation    aggressively    size    manufacturing    line    ultimately    fti    intense    select    cycle    requirement    engineering    ideally    dramatic    drugs    documentation    regulatory    cell    antibody    platform    discovery    expensive    penetration    last    made    global    drug    workflows    gene    diverse    fundraising    relatively    live    diagnostics    provides    therapies    themselves    ex    attributes    manufactured    multiple    sme    validation    market    biologic    decades    workflow    factories    globally    human    life    external    preparation    banks    competitor   

Project "iLCA" data sheet

The following table provides information about the project.

Coordinator		 VALITACELL LTD 

Organization address
address: FOSTERS AVE. - MOUNT MERRION, BLACKROCK
city: DUBLIN 2
postcode: V94
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Ireland [IE]
 Project website https://www.valitacell.com/fti-ilca
 Total cost 3˙483˙633 €
 EC max contribution 2˙438˙543 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VALITACELL LTD IE (DUBLIN 2) coordinator 1˙135˙667.00
2    SOLENTIM LTD UK (WIMBORNE) participant 708˙421.00
3    MICROCOAT BIOTECHNOLOGIE GMBH DE (BERNRIED) participant 594˙454.00

Map

 Project objective

The detailed analysis of live cells, as shed elements of a human disease process, cell therapies themselves or as factories for the production of biologic drugs, is attracting intense focus globally from diverse companies in automation, imaging, diagnostics and manufacturing. This proposal is made on behalf of a consortium of 3 European SME’s to support the validation and preparation for commercial take-up of the market entry application, Cell Line Development [CLD], of a new transformative technology at the forefront of these areas and is ideally suited for cell line development, antibody discovery, gene editing, cell therapy, antibody engineering and ex-vivo diagnostic workflows. Each workflow provides a dramatic increase in insight, control, speed and cost, ultimately resulting in faster, cheaper and more regulatory robust medicines for European patients. Biologic drugs are large in size and are manufactured from a single cell selected following an expensive, relatively crude and time consuming process - Cell Line Development. Our technology can select the 'Top' cell using a detailed analysis of the critical quality attributes along with providing complete image recording and documentation of the growth from a single cell [regulatory requirement]. This cell selection and control is essential as all resulting master and working cell banks are used over the entire life‐cycle of the marketed product that can last multiple decades. This FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery, Cell therapy & ex-vivo diagnostic markets. This is a potentially transformative technology platform in a very large market with 1 current aggressively funded US competitor and our success will ensure competition, continued innovation and most importantly cheaper medicines for European patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ILCA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ILCA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

De-RISC (2019)

De-RISC: Dependable Real-time Infrastructure for Safety-critical Computer

Read More  

PAV-DT (2019)

A disruptive technology that enables low cost real-time monitoring of road pavement condition by any ordinary vehicle circulating on the road, and automatically designs plans for predictive maintenance.

Read More